Biote (BTMD) Common Equity (2020 - 2026)

Biote (BTMD) has reported Common Equity for 7 consecutive years, with -$48.0 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Common Equity rose 43.47% year-over-year to -$48.0 million; the TTM figure through Mar 2026 stood at -$48.0 million (up 43.47% YoY), while the FY2025 annual figure was -$58.5 million, up 42.72% from the prior year.
• Common Equity came in at -$48.0 million for Q1 2026 at Biote, up from -$58.5 million in the prior quarter.
• The five-year high for Common Equity was $10.7 million in Q1 2022, with the low at -$141.5 million in Q2 2024.
• Average Common Equity over 5 years is -$69.7 million, with a median of -$70.8 million recorded in 2022.
• The largest YoY upside for Common Equity was 201.52% in 2022 against a maximum downside of 5136.29% in 2022.
• Year by year, Common Equity stood at -$58.3 million in 2022, then jumped by 37.29% to -$36.5 million in 2023, then tumbled by 179.65% to -$102.2 million in 2024, then surged by 42.72% to -$58.5 million in 2025, then advanced by 18.08% to -$48.0 million in 2026.
• According to Business Quant data, Common Equity over the past three periods registered -$48.0 million, -$58.5 million, and -$65.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.